|
| Press Releases |
|
 |
|
| Friday, May 27, 2022 |
|
|
Legend Capital's Portfolio Company Feima Robotics Assists China's 38th Antarctic Expedition with a Series of Civilian UAV Products |
| On April 26, 2022, the expedition ship Xuelong 2 for China's 38th Antarctic expedition berthed at the Shanghai base dock. So far, China's 38th Antarctic expedition, which lasted 174 days and traveled more than 33,000 nautical miles, has ended successfully. more info >> |
|
| Wednesday, April 27, 2022 |
|
|
Legend Capital's Portfolio Company Xbiome Acquires Clinical-Stage Program Targeting Ulcerative Colitis |
| Legend Capital's portfolio company Xbiome Inc., an industry-leading and AI-driven microbiome therapeutics company, recently announced that it acquired the clinical-stage M201 program from Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and other viral diseases. more info >> |
|
| Tuesday, April 26, 2022 |
|
|
Legend Capital Portfolio: Korean Medical AI Company Lunit to List on KOSDAQ in 2Q2022 |
| Legend Capital's portfolio company Lunit, a Korean Medical AI company, recently announced a preliminary approval from the Korea Exchange for initial public offering (IPO) on the KOSDAQ market, and it plans to submit a registration statement within the second quarter of 2022. more info >> |
|
| Sunday, April 24, 2022 |
|
|
君联资本联合创建企业朗信生物遗传性视网膜变性基因治疗产品在中国获批临床 |
| 君联资本联合创建企业朗信生物（Innostellar Biotherapeutics Co.,Ltd）旗下上海朗昇生物科技有限公司宣布，公司产品LX101注射液用于治疗RPE65双等位基因突变相关的遗传性视网膜变性（IRD）患者的临床试验申请，已获得中国国家药品监督管理局药品审评中心（CDE）批准。 more info >> |
|
|
君聯資本聯合創建企業朗信生物遺傳性視網膜變性基因治療產品在中國獲批臨床 |
| 君聯資本聯合創建企業朗信生物（Innostellar Biotherapeutics Co.,Ltd）旗下上海朗昇生物科技有限公司宣佈，公司產品LX101注射液用於治療RPE65雙等位基因突變相關的遺傳性視網膜變性（IRD）患者的臨床試驗申請，已獲得中國國家藥品監督管理局藥品審評中心（CDE）批准。 more info >> |
|
|
Legend Capital's Co-founded Company Innostellar Biotherapeutics: IRD Gene Therapy Product was Approved for Clinical Trial in China |
| Shanghai Langsheng Biotechnology Co., Ltd., a subsidiary of Legend Capital's co-founded company Innostellar Biotherapeutics more info >> |
|
| Thursday, April 7, 2022 |
|
|
君联资本所投创新型疫苗领军企业瑞科生物在港交所成功上市 |
| 3月31日，君联资本所投创新型疫苗领军企业瑞科生物（股票代码：02179.HK）在港交所成功上市。此次在港上市，成为“香港HPV疫苗第一股”、“香港新型佐剂疫苗第一股”的瑞科生物相信将会给香港资本市场注入新的活力。 more info >> |
|
|
君聯資本所投創新型疫苗領軍企業瑞科生物在港交所成功上市 |
3月31日，君聯資本所投創新型疫苗領軍企業瑞科生物（股票代碼：02179.HK）在港交所成功上市。此次在港上市，成為「香港HPV疫苗第一股」、「香港新型佐劑疫苗第一股」的瑞科生物相信將會給香港資本市場注入新的活力。
more info >> |
|
|
Legend Capital's Portfolio Company Recbio Lists on HKEX Successfully |
| On 31 March 2022, Legend Capital's portfolio company Jiangsu Recbio Technology Co., Ltd. ("Recbio", stock code: 2179.HK), a leading novel vaccines company, went public on the Hong Kong Stock Exchange. more info >> |
|
| Tuesday, March 8, 2022 |
|
|
从边缘走向舞台中央：君联资本所投生物技术产业链上游专精特新企业的奋斗之路 |
| 据联想控股微空间报导，「专精特新」的灵魂是创新，强调「专精特新」就是要鼓励创新。政策目标在于强化科技创新和产业链供应链韧性，加强基础研究，推动应用研究，开展补链强链专项行动，加快解决「卡脖子」难题。联想控股旗下君联资本不仅有幸参与到众多「专精特新」企业的发展中，也践行着将「前瞻性」及「硬科技」作为关键词的投资理念。 more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
35th HKTDC Hong Kong Book Fair opens on 16 July
Jun 24, 2025 20:03: JST
|
|
|
Founders Metals Hits 22.5 m of 11.88 g/t Gold in New Discovery at Maria Geralda
Jun 24, 2025 19:39 HKT/SGT
|
|
|
35th HKTDC Hong Kong Book Fair opens on 16 July
Jun 24, 2025 19:03 HKT/SGT
|
|
|
雲知聲港股招股：衝刺港股「AGI第一股」
Jun 24, 2025 14:35 HKT/SGT
|
|
|
云知声港股招股：冲刺港股AGI第一股
Jun 24, 2025 14:05 HKT/SGT
|
|
|
富士通、誰もが安心して暮らせる仮設住宅の実現に向けて、ミリ波レーダを活用した高齢者見守りの実証実験を実施
Jun 24, 2025 10:30: JST
|
|
|
The Executive Centre Further Expands in Tokyo with New Centres at JP Tower Level 11 and GranTokyo South Tower
Jun 24, 2025 10:00 HKT/SGT
|
|
|
新冠疫情多地爆發 楷和醫療求診數量增
Jun 24, 2025 08:04 HKT/SGT
|
|
|
Two new microalgae genera discovered in Indonesian waters
Jun 24, 2025 07:00 HKT/SGT
|
|
|
ZeptoMetrix Launches H5N1 Control With Phage-Like Particle (PLP) Technology
Jun 23, 2025 21:00 HKT/SGT
|
|
|
Executive Appointments in Connection with the Establishment of NESIC Holdings
Jun 23, 2025 19:22 JST
|
|
|
雲知聲在港招股 AGI獨角獸進入IPO衝刺階段
Jun 23, 2025 17:20 HKT/SGT
|
|
|
云知声在港招股 AGI独角兽进入IPO冲刺阶段
Jun 23, 2025 17:20 HKT/SGT
|
|
|
華領醫藥在2025ADA科學年會公佈多格列艾汀與DPP-4抑制劑聯用在恢復血糖穩態的同時有望降低血脂
Jun 23, 2025 15:09 HKT/SGT
|
|
|
Hua Medicine Announces at 2025 ADA Scientific Sessions that Dorzagliatin Combined with DPP-4 Inhibitor Shows Promise in Reducing Blood Lipids While Restoring Glucose Homeostasis
Jun 23, 2025 13:05 JST
|
|
|
|
|
More News >> |
|
|
|
|
|
